Recent News

Lumena swings for a $75M IPO to bear down on liver diseases

Fierce Biotech
April 3, 2014
Damian Garde

A month removed from raising $45 million in venture backing, San Diego’s Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments.  Read More

RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner

ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner. (more…)

“The Frank Drebin Approach to Healthcare”

“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014.  Read more

ZS Pharma Announces Start of Enrollment of Phase 3 Extended Dosing Study of ZS-9 in Patients with Hyperkalemia

Coppell, Texas – March 25, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. (more…)

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis

SAN DIEGO – March 11, 2014 Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. (more…)

RiverVest is investor in ZS Pharma’s $55 million financing

St. Louis Business Journal
March 7, 2014
Brian Feldt, Reporter

Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round.

ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday. (more…)

Companies To Watch: Otonomy Develops Proprietary Formulation For Ménière’s Disease

Pharmaceutical Online
March 3, 2014
By Wayne Koberstein, executive editor

Not to build a platform, but to create new, FDA -approved therapeutics for unserved indications in the ear, this developer focuses on novel delivery.

ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia

Coppell, Texas – March 5, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. (more…)

Tryton Medical Receives CE-mark for the Left Main Indication

Tryton Medical first & only coronary bifurcation stent indicated for Left Main

 Durham, N.C. – February 13, 2014Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it has received CE Mark for the treatment of Left Main Coronary artery disease. (more…)

ZS Pharma Announces Positive Results from the Extended Treatment Phase of its Phase 3 Trial of ZS-9 in Patients with Hyperkalemia

Coppell, Texas –January 13, 2014ZS Pharma, a specialty pharmaceutical developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Extended Treatment Phase of ZS003, its pivotal Phase 3 trial of ZS-9. ZS-9 is a novel, investigational treatment for hyperkalemia. (more…)

binaural beats . CV Writer . Yaz Lawsuit . best test booster